Influenza And Beyond: Sanofi Pasteur R&D Chief Talks Strategy
Executive Summary
Sanofi Pasteur's R&D chief talks to Scrip about the integration process for Protein Sciences, a vaccine company the group acquired earlier this year in a $650m deal, and how Sanofi Pasteur is using new technologies to speed up vaccine development.
You may also be interested in...
Vaccitech Will Seek Partners For Its Universal Flu Vaccine
Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.